Warfarin and Antiplatelet Therapy in Chronic Heart Failure
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the
oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend
anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in
patients with primary cardiomyopathy, and still others consider it more appropriate in
patients with coronary artery disease (CAD). This absence of consensus reflects the lack of
evidence in this area and different outlooks on the objectives of such therapy (e.g.,
prevention of arterial emboli or reduction in vascular events).
Phase:
Phase 3
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development